Biomedical Research

STENTS WITH GROWTH FACTOR SECRETING MSCS ENHANCED RE-ENDOTHELIALIZATION AND DECREASED RESTENOSIS IN SWINE MODEL

Joint Event on International Conference on CARDIOLOGY AND CARDIOVASCULAR MEDICINE & International Conference on STEM CELLS AND REGENERATIVE MEDICINE
June 18-19, 2018 | Osaka, Japan

Hyun-Kyung

Seoul National University, South Korea

Posters & Accepted Abstracts : Biomed Res

DOI: 10.4066/biomedicalresearch-C2-006

Abstract:

Currently, cardiac stenting is the most effective and least invasive approach to treating the disease. However, in-stent restenosis is a complex chronic side-effect of the stenting treatment. In this study, to reduce stent restenosis and induce reendothelialization within the artery, we applied coronary stents coated with stem cells secreting angiogenic growth factors via an inducible genome-editing system. After confirming the characteristics of the cells and their adhesion properties on the stents, we transplanted the stents into a swine model to evaluate the restenosis and potential therapeutic use of the stents with stem cells. Restenosis was evaluated via optical coherence tomography (OCT), micro-computed tomography (mCT) and angiography, and reendothelialization by immunostaining after cardiac stent treatment. Compared to a bare metal stent (BMS) or a parental umbilical cord blood-derived mesenchymal stem cells (UCB-MSC)-coated stent, the stents that had stem cells capable of the controlled release of hepatocyte growth factor (HGF) and vascular endothelial growth factor (VEGF) successfully reduced re-stenosis within the stent and induced natural re-endothelialization. Furthermore, UCB-MSCs exhibited the ability to differentiate into endothelial cells in Matrigel, and HGF and VEGF improved the differentiation. Our study indicates that the stents coated with UCB-MSCs secreting VEGF/HGF reduced the restenosis side effects of cardiac stenting with improved re-endothelialization.

PDF HTML